Intelligent MoS2–CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/ chemodynamic therapy/ immunotherapy
Rational design of biocompatible nanoplatforms simultaneously realizing multimodal imaging and therapeutic functions is meaningful to cancer treatment. Herein, the MoS2–CuO heteronanocomposites are designed by integrating semiconductor CuO and flower-like MoS2 via a two-step hydrothermal method. Aft...
Gespeichert in:
Veröffentlicht in: | Biomaterials 2021-01, Vol.268, p.120545-120545, Article 120545 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Rational design of biocompatible nanoplatforms simultaneously realizing multimodal imaging and therapeutic functions is meaningful to cancer treatment. Herein, the MoS2–CuO heteronanocomposites are designed by integrating semiconductor CuO and flower-like MoS2 via a two-step hydrothermal method. After loading bovine serum albumin (BSA) and immunoadjuvant imiquimod (R837), the obtained MoS2–CuO@BSA/R837 (MCBR) nanoplatforms realize the excellent computed tomography/infrared thermal/magnetic resonance multi-mode bioimaging as well as significantly enhanced antitumor efficacy of synergetic photothermal therapy (PTT)/chemodynamic therapy (CDT)/immunotherapy. In this nanoplatform, the semiconductor CuO exhibits peroxidase-like activity, which can react with over-expressed H2O2 in tumor microenvironment (TME) to generate OH for CDT via Haber-Weiss and Fenton-like reactions. And this process can be further accelerated by the generated heat of MoS2 under 808 nm laser irradiation. More importantly, the obtained multifunctional MCBR nanoplatforms under near-infrared (NIR) irradiation would destroy tumor cells to generate tumor associated antigens (TAAs), which combine with R837 as an adjuvant to trigger strong antitumor immune responses for effectively eliminating primary tumors and metastatic tumors. |
---|---|
ISSN: | 0142-9612 1878-5905 |
DOI: | 10.1016/j.biomaterials.2020.120545 |